Status:

COMPLETED

In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Obesity

Overweight

Eligibility:

All Genders

Brief Summary

This study is conducted in Europe. The aim of this study is to investigate the usage of liraglutide for weight management in clinical practice using the CPRD (Clinical Practice Research Datalink) prim...

Eligibility Criteria

Inclusion

  • New initiators of liraglutide (unbranded, or branded prescription, i.e. Saxenda® or Victoza®), who have no liraglutide prescriptions in the twelve months prior to index date (time of first prescription). Patients must be research standard (registered as "acceptable" in the database) with at least one year of up-to-standard registration prior to their index date

Exclusion

  • Not applicable

Key Trial Info

Start Date :

April 20 2018

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 12 2022

Estimated Enrollment :

105 Patients enrolled

Trial Details

Trial ID

NCT03479762

Start Date

April 20 2018

End Date

September 12 2022

Last Update

November 25 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Novo Nordisk Investigational Site

Soeborg, Denmark, 2860

In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database | DecenTrialz